Murine neutralizing antibody response and toxicity to synthetic peptides derived from E1 and E2 proteins of hepatitis C virus

Vaccine

Volumn 28, Issue 52, 2010, Pages 8338-8344

  El Awady, Mostafa K ^a   Tabll, Ashraf A ^a   Yousif, Hassan ^a   El Abd, Yasmin ^a   Reda, Mohamed ^a   Khalil, Samy B ^d   El Zayadi, Abdel Rahman ^b   Shaker, Maysa H ^c   Bader El Din, Noha G ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c ANIMAL HEALTH RESEARCH INSTITUTE   (Egypt)

^d US Naval Medical Research Unit No 3 Egypt   (Egypt)

Author keywords

Experimental animals; Hepatitis C virus; Peptide; Vaccine

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; IMMUNOGLOBULIN G ANTIBODY; PEPTIDE VACCINE; PROTEIN P 36; PROTEIN P35; PROTEIN P37; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS ATTACHMENT;

ANIMALS; ANTIBODIES, NEUTRALIZING; FEMALE; HEPATITIS C ANTIBODIES; MALE; MICE; VACCINATION; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 78649740931     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.059     Document Type: Article

References (28)

1. Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med 2001, 345(July (1)):41-52.
2. Bowen D.G., Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436(August (7053)):946-952.
3. Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007, 27(May (2)):152-160.
4. Zinkernagel R.M. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med 2001, 345(November (18)):1331-1335.
5. Bartenschlager R., Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res 2007, 127(August (2)):195-207.
6. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004, 85(November (Pt 11)):3173-3188.
7. El-Awady M.K., Tabll A., El-Abd Y., Yousif H., Hegab M., Reda M., et al. Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats. Virol J 2009, 6(May (1)):66.
8. El-Awady M.K., Tabll A.A., Atef K., Yousef S.S., Omran M.H., El-Abd Y., et al. Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro. World J Gastroenterol 2006, 12(April (16)):2530-2535.
9. El-Awady M.K., El-Demellawy M.A., Khalil S.B., Galal D., Goueli S.A. Synthetic peptide-based immunoassay as a supplemental test for HCV infection. Clin Chim Acta 2002, 325(November (1-2)):39-46.
10. Weiner A.J., Paliard X., Selby M.J., Medina-Selby A., Coit D., Nguyen S., et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 2001, 75(August (15)):7142-7148.
11. Lanford R.E., Guerra B., Chavez D., Bigger C., Brasky K.M., Wang X.H., et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004, 78(February (3)):1575-1581.
12. Simmonds P., Bukh J., Combet C., Deléage G., Enomoto N., Feinstone S., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42(October (4)):962-973.
13. Kuiken C., Yusim K., Boykin L., Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005, 21(February (3)):379-384.
14. Vietheer P.T., Boo I., Drummer H.E., Netter H.J. Immunizations with chimeric hepatitis B virus-like particles to induce potential antihepatitis C virus neutralizing antibodies. Antivir Ther 2007, 12:477-487.
15. Torresi J., Stock O.M., Fischer A.E., Grollo L., Drummer H., Boo I., et al. A self-adjuvanting multiepitope immunogen that induces a broadly crossreactive antibody to hepatitis C virus. Hepatology 2007, 45(April (4)):911-920.
16. Tabll A., Khalil S., El-Shenawy R., Esmat G., Helmy A., Attallah A., et al. Establishment of hybrid cell lines producing monoclonal antibodies to a synthetic peptide from E1 region of the hepatitis C virus. J Immunoassay Immunochem 2008, 29:91-104.
17. Posnett D.N., McGrath H., Tam J.P. A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T-cell antigen beta-chain. J Biol Chem 1988, 263(February (4)):1719-1725.
18. Tam J.P. Synthetic peptide vaccine design: synthesis and properties of a high density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988, 85:5409-5413.
19. Schofield D.J., Bartosch B., Shimizu Y.K., Allander T., Alter H.J., Emerson S.U., et al. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 2005, 42(November (5)):1055-1062.
20. Eren R., Landstein D., Terkieltaub D., Nussbaum O., Zauberman A., Ben-Porath J., et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006, 80(March (6)):2654-2664.
21. Heile J.M., Fong Y.L., Rosa D., Berger K., Saletti G., Campagnoli S., et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol 2000, 74(August (15)):6885-6892.
22. Martínez-Donato G., Capdesuñer Y., Acosta-Rivero N., Rodríguez A., Morales-Grillo J., Martínez E., et al. Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice. Mol Biotechnol 2007, 35(March (3)):225-235.
23. Abraham J.D., Himoudi N., Kien F., Berland J.L., Codran A., Bartosch B., et al. Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 2004, 22(September (29-30)):3917-3928.
24. Majid A.M., Ezelle H., Shah S., Barber G.N. Evaluating replication defective vesicular stomatitis virus as a vaccine vehicle. J Virol 2006, 80(July (14)):6993-7008.
25. Elmowalid G.A., Qiao M., Jeong S.H., Borg B.B., Baumert T.F., Sapp R.K., et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007, 104(May (20)):8427-8432.
26. Ma X., Forns X., Gutierrez R., Mushahwar I.K., Wu T., Payette P.J., et al. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG optimized vectors in mice. Vaccine 2002, 20(September (27-28)):3263-3271.
27. Lechmann M., Liang T.J. Vaccine development for hepatitis C. Semin Liver Dis 2000, 20(2):211-226.
28. Fournillier A., Depla E., Karayiannis P., Vidalin O., Maertens G., Trépo C., et al. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol 1999, 73(September (9)):7497-7504.